These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 15990700

  • 1. COX-2 inhibitors and metabolism of essential fatty acids.
    Das UN.
    Med Sci Monit; 2005 Jul; 11(7):RA233-7. PubMed ID: 15990700
    [Abstract] [Full Text] [Related]

  • 2. Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
    Das UN.
    J Assoc Physicians India; 2005 Jul; 53():623-7. PubMed ID: 16190133
    [Abstract] [Full Text] [Related]

  • 3. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems.
    Sharma S, Sharma SC.
    Indian J Exp Biol; 1997 Oct; 35(10):1025-31. PubMed ID: 9475035
    [Abstract] [Full Text] [Related]

  • 4. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies.
    Tapiero H, Ba GN, Couvreur P, Tew KD.
    Biomed Pharmacother; 2002 Jul; 56(5):215-22. PubMed ID: 12199620
    [Abstract] [Full Text] [Related]

  • 5. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ.
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [Abstract] [Full Text] [Related]

  • 6. [Biology of essential fatty acids (EFA)].
    Dobryniewski J, Szajda SD, Waszkiewicz N, Zwierz K.
    Przegl Lek; 2007 Jun; 64(2):91-9. PubMed ID: 17892040
    [Abstract] [Full Text] [Related]

  • 7. Essential fatty acids: biochemistry, physiology and pathology.
    Das UN.
    Biotechnol J; 2006 Apr; 1(4):420-39. PubMed ID: 16892270
    [Abstract] [Full Text] [Related]

  • 8. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA, Delafontaine P.
    J Am Coll Cardiol; 2004 Feb 18; 43(4):519-25. PubMed ID: 14975457
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E.
    Ann Clin Lab Sci; 2005 Feb 18; 35(4):347-85. PubMed ID: 16254252
    [Abstract] [Full Text] [Related]

  • 10. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.
    Das UN.
    Lipids Health Dis; 2008 Oct 15; 7():37. PubMed ID: 18922179
    [Abstract] [Full Text] [Related]

  • 11. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA.
    Science; 2002 Apr 19; 296(5567):539-41. PubMed ID: 11964481
    [Abstract] [Full Text] [Related]

  • 12. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV, Lally ET, Moore PA.
    Curr Med Res Opin; 2005 Aug 19; 21(8):1217-26. PubMed ID: 16083531
    [Abstract] [Full Text] [Related]

  • 13. Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2.
    Levin G, Duffin KL, Obukowicz MG, Hummert SL, Fujiwara H, Needleman P, Raz A.
    Biochem J; 2002 Jul 15; 365(Pt 2):489-96. PubMed ID: 11939906
    [Abstract] [Full Text] [Related]

  • 14. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
    Velázquez C, Praveen Rao PN, Knaus EE.
    J Med Chem; 2005 Jun 16; 48(12):4061-7. PubMed ID: 15943479
    [Abstract] [Full Text] [Related]

  • 15. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance.
    Poorani R, Bhatt AN, Dwarakanath BS, Das UN.
    Eur J Pharmacol; 2016 Aug 15; 785():116-132. PubMed ID: 26335394
    [Abstract] [Full Text] [Related]

  • 16. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
    Sakata C, Kawasaki T, Kato Y, Abe M, Suzuki K, Ohmiya M, Funatsu T, Morita Y, Okada M.
    Thromb Res; 2013 Jul 15; 132(1):56-62. PubMed ID: 23522855
    [Abstract] [Full Text] [Related]

  • 17. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K, Rigas B.
    Biochem Pharmacol; 2005 Oct 01; 70(7):969-86. PubMed ID: 15949789
    [Abstract] [Full Text] [Related]

  • 18. Getting to the heart of COX-2 inhibition.
    Breyer MD.
    Cell Metab; 2005 Sep 01; 2(3):149-50. PubMed ID: 16154096
    [Abstract] [Full Text] [Related]

  • 19. Fatty acid facts, Part III: Cardiovascular disease, or, a fish diet is not fishy.
    Pauwels EK, Kostkiewicz M.
    Drug News Perspect; 2008 Dec 01; 21(10):552-61. PubMed ID: 19221636
    [Abstract] [Full Text] [Related]

  • 20. "Cell Membrane Theory of Senescence" and the Role of Bioactive Lipids in Aging, and Aging Associated Diseases and Their Therapeutic Implications.
    Das UN.
    Biomolecules; 2021 Feb 08; 11(2):. PubMed ID: 33567774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.